CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 206 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2024. The put-call ratio across all filers is 1.19 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $8,133,820 | -1.8% | 181,599 | +2.6% | 0.00% | 0.0% |
| Q1 2024 | $8,282,702 | +35.5% | 176,943 | +3.0% | 0.00% | +100.0% |
| Q4 2023 | $6,113,961 | +15.9% | 171,837 | -3.1% | 0.00% | 0.0% |
| Q3 2023 | $5,275,073 | +679.0% | 177,373 | +372.0% | 0.00% | – |
| Q2 2023 | $677,138 | +9.8% | 37,577 | -2.2% | 0.00% | – |
| Q1 2023 | $616,865 | +84.4% | 38,410 | +110.1% | 0.00% | – |
| Q4 2022 | $334,543 | -8.6% | 18,281 | -2.0% | 0.00% | – |
| Q3 2022 | $366,000 | -6.2% | 18,647 | -10.9% | 0.00% | – |
| Q2 2022 | $390,000 | -8.2% | 20,919 | +8.1% | 0.00% | – |
| Q1 2022 | $425,000 | -92.1% | 19,343 | -89.8% | 0.00% | -100.0% |
| Q4 2021 | $5,404,000 | +1457.3% | 190,235 | +1052.9% | 0.00% | – |
| Q3 2021 | $347,000 | +34.5% | 16,501 | +20.4% | 0.00% | – |
| Q2 2021 | $258,000 | – | 13,702 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |